Gapping down
In reaction to disappointing earnings/guidance: STLD -3.6%.
Select drug related names showing modest weakness: GSK -1.0%, AZN -0.7%.
Other news: DSCO -11.4% (announces that it intends to offer shares of common stock and common stock purchase warrants ), SCEI -10.9% (announces proposed public offering of common stock), CPSI -4.3% (to investigate issues related to suspected misappropriation of assets by VP of Finance and CFO), DRE -3.9% (to offer 23 million shares of common stock; announces acquisition of joint venture partner's interest in industrial portfolio), ICE -2.5% (still checking), XCO -2.5% (announces agreement to acquire Haynesville/Bossier shale properties from SWN for ~$355 mln), BKCC -1.9% (priced its public offering of 7.5 mln shares of its common stock at an offering price of $10.25 per share, raising $76.9 mln of gross proceeds), FCH -1.6% (prices 27.5 mln share common stock offering at $5.50 per share).
Analyst comments: DTV -1.9% (downgraded to Market Perform from Outperform at Wells Fargo).
Gapping up
In reaction to strong earnings/guidance: PIR +8.2%, SJM +3.4%, CFI +2.0%.
Select financial related names showing strength: RBS +4.2%, UBS +3.1%, LYG +3.0%, BCS +2.8%, STD +2.5%, BBVA +2.3%, CS +1.9%, DB +1.6%, SNV +1.4%, AIG +1.4%, HBC +1.2%.
Select oil/gas related names showing strength: RIG +4.2%, SUN +3.2% (Hearing stock also getting boost from analyst upgrade), ATPG +2.9%, APC +1.5%, BP +1.4%, TOT +1.1%.
Select solar names ticking higher boosted by FSLR upgrade and reports that Germany may pull back on subsidy cuts: FSLR +4.4% (upgraded to Outperform from Neutral at Credit Suisse), TSL +3.0%, JASO +2.1%, SOLF +2.0%.
Other news: NBIX +8.2% (announces it has established a worldwide collaboration with Boehringer Ingelheim to research and develop small molecule GPR119 agonists for the treatment of Type II diabetes and other indications ), NVDA +3.7% (Cramer makes positive comments on MadMoney), CRUS +3.6% (Cramer makes positive comments on MadMoney), CLH +2.5% (checking for anything specific), TXT +1.9% (Bell Helicopter Textron awarded $546,001,600 contract - DoD ), SAP +1.8% (still checking for anything specific), AIXG +1.5% (still checking), HGSI +1.4% (Human Genome and GlaxoSmithKline announce presentation at EULAR of BLISS-52 Phase 3 SLE study results for BENLYSTA).
Analyst comments: ANAD +5.0% (light volume; upgraded to Buy at Stifel Nicolaus), AAPL +0.8% (initiated with Buy at Janney).